文献速递肝病

肝硬化患者骨骼肌丢失速率及临床预测因素

Rate and clinical predictors of skeletal muscle loss in patients with cirrhosis.
PubMed 文献 · Gut · 2026-07-30

该队列研究纳入364例等待肝移植的肝硬化门诊患者,中位年龄62岁,68%男性,MELD-Na中位12。中位SMI年变化率为-1.6%,快速肌少症丢失(RML,最差四分位<-7.4%)独立预测等待期死亡率(HR 3.43-3.52),并与腹水和较高MELD-Na相关。

要点

  • 肝硬化患者中位骨骼肌丢失速率为每年1.6%。
  • RML定义为SMI年变化率最差四分位(<-7.4%)。
  • RML独立预测等待期死亡率,12个月32% vs 10%,24个月75% vs 27%。

核心结论

  • 肝硬化患者中位骨骼肌丢失为每年1.6%,快速肌少症丢失独立预测等待期死亡率。

研究设计与样本

  • 队列研究纳入364例在三级中心等待肝移植的肝硬化门诊成人患者,2015年2月至2021年1月间至少接受两次腹部CT。
  • 量化L3骨骼肌指数并按身高标准化,计算SMI年化百分比变化(ΔSMI/year%)。

主要发现

  • 中位(IQR)ΔSMI/year%为-1.6%(-7.4至+3.7)。
  • 快速肌少症丢失定义为ΔSMI/year%最差四分位(<-7.4%,n=91)。
  • RML独立预测因素包括腹水(OR 1.77,95%CI 1.00至3.12)和较高MELD-Na(OR 1.06,95%CI 1.00至1.13)。
  • RML组与非RML组等待期累积死亡率12个月分别为32% vs 10%,24个月分别为75% vs 27%(log-rank p<0.001)。
  • 调整Cox模型中RML独立预测等待期死亡率(HR 3.43-3.52)。

关键数值与推荐

  • 快速肌少症丢失定义为ΔSMI/year%最差四分位(<-7.4%)。
  • 等待期死亡率定义为死亡或因病情过重而退出移植名单。

临床怎么用

  • 对等待肝移植的肝硬化患者,尤其合并腹水或较高MELD-Na者,应关注骨骼肌丢失。
  • ΔSMI/year%可用于识别快速肌少症丢失高风险患者,辅助预后评估。

局限性

  • 单中心队列研究,仅纳入等待肝移植的门诊患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skeletal muscle mass predicts outcomes in cirrhosis and represents a therapeutic target. However, the natural rate of muscle change in this population remains poorly defined. OBJECTIVE: We characterised longitudinal skeletal muscle change and its association with clinical outcomes in cirrhosis. DESIGN: This cohort study enrolled ambulatory adults with cirrhosis awaiting liver transplantation at a tertiary centre who underwent at least two abdominal CT scans between February 2015 and January 2021. Skeletal muscle index (SMI) at L3 was quantified and normalised for height. Annualised percent change in SMI (ΔSMI/year%) was calculated. The primary outcome was waitlist mortality, defined as death or delisting for being too ill for transplantation. RESULTS: Among 364 patients (median age 62 years; 68% male; model for end-stage liver disease-sodium (MELD-Na) 12), the median (IQR) ΔSMI/year% was -1.6% (-7.4 to +3.7). Rapid muscle loss (RML) was defined as the worst quartile of ΔSMI/year% (< -7.4%; n=91). Independent predictors of RML included ascites (OR 1.77, 95% CI 1.00 to 3.12) and higher MELD-Na (OR 1.06, 95% CI 1.00 to 1.13). Cumulative waitlist mortality was significantly higher in patients with RML than in those without RML at 12 months (32% vs 10%) and 24 months (75% vs 27%) (log-rank p<0.001). RML independently predicted waitlist mortality in adjusted Cox models (HR 3.43-3.52). CONCLUSION: Patients with cirrhosis had a median skeletal muscle loss of 1.6%/year. In this cohort, RML independently predicted waitlist mortality and was associated with ascites and MELD-Na. These data could inform effect-size estimates for future trials targeting sarcopenia in cirrhosis with low-to-moderate MELD-Na.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Yang TC, Ha NB, Fan B, et al. Rate and clinical predictors of skeletal muscle loss in patients with cirrhosis. Gut. 2026. PMID: 42532672. doi:10.1136/gutjnl-2026-339159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。